The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer
Abstract
The activating mutation BRAFV600E is a frequent genetic event in papillary thyroid carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radioiodide-refractory metastatic disease. The molecular basis of such an aggressive behavior induced by BRAF remains unclear. Here, we show a mechanism through which BRAF induces NIS repression and promotes epithelial to mesenchimal transition and invasion based on the operation of an autocrine transforming growth factor (TGF)β loop. BRAF induces secretion of functional TGFβ and blocking TGFβ/Smad signaling at multiple levels rescues BRAF-induced NIS repression. Although this mechanism is MAP/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK independent, secreted TGFβ cooperates with MEK-ERK signaling in BRAF-induced cell migration, Matrigel invasion, and EMT. Consistent with this process, TGFβ and other key components of TGFβ signaling, such as TβRII and pSmad2, are overexpressed in human PTC, suggesting a widespread activation of this pathway by locally released TGFβ. Moreover, this high TGFβ/Smad activity is associated with PTC invasion, nodal metastasis, and BRAF status. Interestingly, TGFβ is overexpressed in the invasive front, whereas NIS is preferentially expressed in the central regions of the tumors, suggesting that this negative correlation between TGFβ and NIS occurs locally inside the tumor. Our study describes a novel mechanism of NIS repression in thyroid cancer and provides evidence that TGFβ may play a key role in promoting radioiodide resistance and tumor invasion during PTC progression. [Cancer Res 2009;69(21):8317–25]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PTC patients with RET/PTC rearrangements [30–32] or the BRAFV600E mutation [33, 34] exhibit cell dedifferentiation.”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [33]
Citations
Cites
2 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 305
RetractedMelillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22758 · Cited by 298
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R. L., Itoh, S., Kawabata, M., Heldin, N., Heldin, C., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,796
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,223
Cloning and characterization of the thyroid iodide transporter
Dai, G., Levy, O., & Carrasco, N. (1996) · Nature · doi:10.1038/379458a0 · Cited by 1,109
Self-citationTargeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt, J. S., & Herrera, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1503 · Cited by 1,103
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,036
Cited by
Sorted by citations
Items 201–265 of 265
Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer
Tuccilli, C., Baldini, E., Arlot‐Bonnemains, Y., Chesnel, F., Sorrenti, S., Vito, C. D., D’Armiento, E., Antonelli, A., Fallahi, P., Watutantrige‐Fernando, S., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3907 · Cited by 8
Genetic mutations, molecular markers and future directions in research
Patel, K. N. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.437 · Cited by 6
Ezzat, S., Pasternak, J. D., Rajaraman, M. M., Abdel-Rahman, O. M., Boucher, A., Chau, N. G., Chen, S., Gill, S., Hyrcza, M. D., Lamond, N. W. D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1437360 · Cited by 6
Papillary thyroid cancer immune phenotypes via tumor-infiltrating lymphocyte spatial analysis
Nam, M., Yang, W., Kim, H. S., Park, J., Park, G., Kim, S., Song, S., Ock, C., Wang, V. G., Chuang, J. H., et al. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0110 · Cited by 6
Yang, D., Wang, C., Luo, Y., Li, X., Song, Q., Zhang, J., & Xin, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178908 · Cited by 6
Jones, H., Green, V., England, J. A., & Greenman, J. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0041 · Cited by 6
Comparative effects of transforming growth factor beta isoforms on redox metabolism in thyroid cells
Oglio, R., Thomasz, L., Salvarredi, L. A., Juvenal, G. J., & Pisarev, M. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.10.011 · Cited by 6
Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review
Gao, Y., & Zheng, H. S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104484 · Cited by 6
MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol
Kocabaş, G. Ü., Blatti, A. K., Berdeli, A., Özgen, G., & Yürekli, B. Ş. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155623 · Cited by 5
Saha, S., Tandon, R., Sanku, J., Kumari, A., Shukla, R., & Srivastava, N. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125463 · Cited by 6
Prognostic Factors for Thyroid Carcinoma Originating from Follicular Cells
Ito, Y., McIver, B., Bešič, N., & Agarwal, A. (2011) · Journal of Thyroid Research · doi:10.1155/2012/920631 · Cited by 4
Carro, G. H., & Nicola, J. P. (2023) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2023.100492 · Cited by 4
Dao, B. D., Lingvay, I., Sailors, J. L., Landay, M. J., & Shapiro, G. A. (2015) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709615603723 · Cited by 4
Liu, L., Shi, Y., Lai, Q., Huang, Y., Jiang, X., Liu, Q., Huang, Y., Xia, Y., Xu, D., Jiang, Z., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.865909 · Cited by 4
Wang, P., Yu, L., Fu, Y., Wang, F., Zhao, S., Wang, Y., & Hou, X. (2017) · Oncology Research and Treatment · doi:10.1159/000477909 · Cited by 4
Rokashkov, V. D., Спирина, Л. В., Викторовна, Т. Н., & Chizhevskaya, S. Y. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040362 · Cited by 3
Yu, Q., Chen, J., Chen, Z., Yu, L., Zhu, Y., Xi, X., & Du, B. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.07.002 · Cited by 3
Targeting the BRAF Signaling Pathway in CD133pos Cancer Stem Cells of Anaplastic Thyroid Carcinoma
Bozorg-Ghalati, F., Hedayati, M., Dianatpour, M., Mosaffa, N., & Azizi, F. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.5.1353 · Cited by 3
Shimamura, M. I., Nakahara, M., Kurashige, T., Yasui, K., Nakashima, M., & Nagayama, Y. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0475 · Cited by 3
Choi, J. H., Hong, Y. O., Kim, H., & Jung, A. R. (2021) · Thyroid Research · doi:10.1186/s13044-021-00115-z · Cited by 3
Kobrynska, N. Y., Pushkarev, V. M., Левчук, Н. І., Ковзун, О. І., Komisarenko, І. І., Guda, B. B., & Tronko, M. D. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.4.2025.1560 · Cited by 2
Yang, H., Koehler, V. F., Nagarajah, J., Schmohl, K. A., Stauss, C., Schwenk, N., Spellerberg, R., Kitzberger, C., Kumbrink, J., Zach, C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.033 · Cited by 2
Yamin, T., Cohen, O. M., Robenshtok, E., Izkhakov, E., Miodovnik, M., Gutfeld, O., Leshem, Y., Meirovitz, R., Warshavsky, A., Muhanna, N., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1694805 · Cited by 2
Autophagy in thyroid cancer: Immune suppression and drug resistance
Zhai, H., Sun, P., Bashir, B., Qu, B., Du, Z., Kumar, A. P., Xia, Y., Gangadaran, P., Jha, S. K., Singh, S. K., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101437 · Cited by 2
Ayala, M. D., Gabiña, P. M., Paja, M., Bilbao‐González, A., Expósito-Rodríguez, A., & de Zarate, E. R. O. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03343-4 · Cited by 2
He, Z., Wang, C., Liu, C., Zhang, K., Wang, J., Wang, X., Zhang, Y., & Chen, L. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0298 · Cited by 2
Ras Oncoprotein Disrupts the TSH/CREB Signaling Upstream Adenylyl Cyclase in Human Thyroid Cell
Salzano, M., Russo, E., Salzano, S., Bifulco, M., & Vitale, M. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24672 · Cited by 2
Effects of the Smad4 C324Y mutation on thyroid cell proliferation
D'inzeo, S., Nicolussi, A., NARDI, F., & Coppa, A. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1908 · Cited by 2
Emerging Therapeutics for Radioiodide-Refractory Thyroid Cancer
Nicola, J. P., & Masini-Repiso, A. M. (2016) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2016.05.02.5 · Cited by 2
BRAF Mutation and its effects on Radioiodine Uptake in Patients with Anaplastic Thyroid Cancer
Bozorg-Ghalati, F., & Hedayati, M. (2016) · Cited by 2
Branigan, G. P., Casado‐Medrano, V., O’Neill, A., Ricarte‐Filho, J. C., Massoll, N. A., Salwen, M., Spangler, Z., Scheerer, M., Williamson, E. K., Bauer, A. J., et al. (2023) · Cancers · doi:10.3390/cancers15030879 · Cited by 2
Yu, M., Deng, Z., Wang, K., & Zhang, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1537221 · Cited by 1
Bauer, A. J., & Francis, G. L. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.68 · Cited by 1
The Management of Thyroid Nodules and Cancer in the Molecular Era
Zhou, L. H., & Patel, K. N. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.15.18 · Cited by 1
Mitchell, B. C., Leone, D. A., Yang, S., Khan, A. A., Mahalingam, M., & Dhingra, J. K. (2016) · PubMed Central · Cited by 1
Thérapies ciblées en oncologie endocrinienne : facteurs pronostiques et prédictifs de réponse
Hescot, S., Baudin, É., Borson‐Chazot, F., & Lombès, M. (2013) · Annales d Endocrinologie · doi:10.1016/s0003-4266(13)70017-9 · Cited by 1
Modern approaches to the treatment of radioiodine-refractory differentiated thyroid cancer
Da, D., & Sd, M. (2021) · Radiation Diagnostics Radiation Therapy · doi:10.37336/2707-0700-2021-1-4 · Cited by 1
Barry, S. L., Lynch, E., Bredin, P., McWilliams, S., McCarthy, J. E., O’Mahony, O., Feeley, L., Nugent, K., Sheahan, P. O., O'Hanlon, D. M., et al. (2024) · Onco · doi:10.3390/onco4040030 · Cited by 1
Molecular Aspects of Thyroid Cancer in Children
Bauer, A. J., & Francis, G. L. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3314-3_4 · Cited by 1
Author response: Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
Anelli, V., Villefranc, J. A., Chhangawala, S., Martinez-McFaline, R., Riva, E., Nguyen, A., Verma, A., Bareja, R., Chen, Z., Scognamiglio, T., et al. (2017) · eLife · doi:10.7554/elife.20728.020 · Cited by 1
Read, M. L., Brookes, K., Thornton, C. E. M., Fletcher, A., Alshahrani, M., Khan, R., Nieto, H. R., de Souza, P. B., Webster, J., Alderwick, L. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.21.213967 · Cited by 1
Molecular characterisation of benign and malignant thyroid dysfunction
Bakhsh, A. (2014) · ORCA Online Research @Cardiff (Cardiff University)
Schott, M. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79511-1
O cluster de microRNAs miR-17-92 e seus alvos na oncogênese tiroidiana: influência de
Fuziwara, C. S. (2014)
Oncogenic events and therapeutic targets in thyroid cancer
Fagin, J. A., & Filho, J. C. R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.065
Fletcher, A., Read, M. L., Thornton, C. E. M., Larner, D. P., Poole, V. L., Brookes, K., Nieto, H. R., Alshahrani, M., Thompson, R. J., Lavery, G. G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622241
Paunovic, I. R., Šelemetjev, S., Denčić, T. I., Đorić, I., Janković, J., Rončević, J., & Cvejic, D. S. (2019) · Archives of Biological Sciences · doi:10.2298/abs190920064p
Oxidative Stress and Thyroid Disorders
Periyasamy, L., Babu, K. N., Krishnamoorthy, S., Behlen, J. C., Muthusami, S., & Stanley, J. A. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_1-1
Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions
Lugat, A., Gaschet, J., Chérel, M., Allard, M., Guérard, F., Kraeber‐Bodéré, F., & Ansquer, C. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_34
Dupuy, C., Radom, M., Buffet, C., Cazarin, J., Harinquet, M., de Faria, C. C., Brayé, F., Nobre, C., Aglave, M., Mesloub, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5138035
NOX4 prevents the recruitment of PAX8 and NKX2.1 to chromatin in BRAF-mutated thyroid cancer cellsPreprint
Radom, M., Buffet, C., Cazarin, J., Harinquet, M., de Faria, C. C., Brayé, F., Nobre, C., Aglave, M., Mesloub, Y., Dayris, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.14.647724
Aycan, Z., Çetin, S. K., Kıvrak, H., Çevik, B., Ceyhan, K., Şıklar, Z., Berberoğlu, M., Özsu, E., Fitöz, Ö. S., & Sak, S. D. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549373
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Rôle du Symporteur Sodium Iodure dans la carcinogenèse non thyroïdienne
Nader, M. B. (2014) · theses.fr (ABES) · doi:10.70675/76d753c1z6a3az4b97zbca9z6e471bad9200
Hou, G., & Gao, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1795263
FOXP Transcription Factors in Thyroid Cancer: From Molecular Expression to Clinical Significance
Vasiljević, T., Kokanov, N., & Kožik, B. (2026) · Biomedicines · doi:10.3390/biomedicines14061222
Microenvironmental Control of Thyroid Cancer Plasticity and Radioiodine Resistance
Ye, Q., & Yu, X.-P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167305
Ashtari, S., Mehrabi, M. M., & Güleç, S. (2026) · Cancers · doi:10.3390/cancers18162697
Upregulation of RARA-AS1, a novel long noncoding RNA, is associated with thyroid cancer development
Lotfimanesh, N., Yari, A., Abdolzadeh, S., Pourbagherian, O., Jebelli, A., & Mokhtarzadeh, A. A. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102631
Petkova, V., Dodova, R., Видинов, К., & Kaneva, R. P. (2026) · Cancers · doi:10.3390/cancers18203406
Metadata
- Authors
- Riesco-Eizaguirre, G., Rodríguez, I., De la Vieja, A., Costamagna, E., Carrasco, N., Nistal, M., & Santisteban, P.
- Affiliations
- 1Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas y Universidad Autónoma de Madrid; 2Servicio de Endocrinología y Nutrición and 3Departamento de Anatomía Patológica, Hospital Universitario La Paz; and 4Área de Biología Celular y Desarrollo, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; and 5Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York
- Albert Einstein College of Medicine (US)
- Venue
- Cancer Research
- Published
- 2009-10-28
- Volume
- 69
- Issue
- 21
- Pages
- 8317-8325
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2139518879
- Cited by
- 265
- References
- 37
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 7 · 2023: 13 · 2022: 12 · 2021: 22 · 2020: 11 · 2019: 19 · 2018: 18 · 2017: 13 · 2016: 15 · 2015: 24 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Instituto de Salud Carlos III
- National Cancer Institute (R01CA098390, CA098390)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- BRAF V600E mutation, papillary thyroid carcinoma, TGF-beta, sodium iodide symporter, epithelial-mesenchymal transition, tumor invasion, lymph node metastasis, MEK/ERK signaling, Smad2, TGFBR2, cell migration
- MeSH terms
- Sodium-Iodide Symporters, Adult, Carcinoma, Papillary, Enzyme-Linked Immunosorbent Assay, Female, Fluorescent Antibody Technique, Humans, Immunoenzyme Techniques, Iodides, Luciferases, Male, Mutation, Neoplasm Invasiveness, RNA, Messenger, Thyroid Neoplasms, Tumor Cells, Cultured, Blotting, Western, Down-Regulation, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Receptors, Transforming Growth Factor beta, Autocrine Communication, Reverse Transcriptase Polymerase Chain Reaction, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, Symporters, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Smad2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
